Given the increased MEK activation observed in MES-like tumor cells from NF1-mutant glioblastomas and the clinical approval of multiple MEK inhibitors for NF1-mutant nervous system tumors (13, 33, 34), we next sought to functionally evaluate the therapeutic relevance of MEK inhibition. This evidence concerns the gene MAP2K7 and nervous system neoplasm.